GSK plc will present new data from its haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, reinforcing the potential of its therapies to redefine outcomes for patients with difficult-to-treat blood cancers. Updated findings from the DREAMM clinical programme for belantamab mafodotin further highlight its ability to extend remission in relapsed or refractory multiple myeloma, with ongoing development in newly diagnosed patients. New analyses explore depth and duration of response, progression-free survival benefits, minimal residual disease negativity rates and treatment effects in functionally high-risk patient populations that typically experience poorer outcomes. Additional data from DREAMM-9 also examine how optimised dosing strategies may enhance responses while helping to minimise eye-related side effects.

GSK will also share new analyses for momelotinib, building on the results of the MOMENTUM and SIMPLIFY trials. These analyses assess spleen and anaemia endpoints together with overall survival. Early findings from the ODYSSEY combination trial will be presented, providing initial insight into whether momelotinib’s unique dual mechanism—targeting both anaemia and splenomegaly—can position it as a backbone therapy for future combinations aimed at delivering deeper and more durable responses. Further analyses explore how higher momelotinib exposure may be linked to greater anaemia-related benefits and evaluate survival outcomes in intermediate- and high-risk patients who switched from standard-of-care therapies.

Multiple myeloma remains the third most common blood cancer worldwide. Although considered treatable, it is not yet curable, and resistance to existing therapies is common. With a large proportion of patients receiving treatment in community oncology settings, there is a strong need for effective therapies that offer manageable side effects and can be administered outside highly specialised centres. Myelofibrosis, another focus of the data presented, is a rare blood cancer marked by enlarged spleen, severely reduced blood counts and debilitating symptoms driven by dysregulated JAK-STAT signalling and excessive cytokine production.

Belantamab mafodotin, a monoclonal antibody-drug conjugate targeting BCMA, combines a humanised antibody with a cytotoxic agent using a non-cleavable linker. It has already received approvals in several major markets in combination regimens for patients with relapsed or refractory multiple myeloma and is currently under review in additional countries. The therapy recently secured US FDA approval under the brand name Blenrep for use with bortezomib and dexamethasone in adults who have received at least two prior lines of treatment.

Momelotinib offers a differentiated mechanism of action by inhibiting JAK1, JAK2 and ACVR1. This profile may help improve symptoms, reduce spleen volume and provide meaningful anaemia benefits by lowering circulating hepcidin. The therapy was approved by the US FDA in September 2023 under the brand name Ojjaara for adults with intermediate or high-risk myelofibrosis who also have anaemia.